Needham & Company Starts Neothetics Inc. (NEOT) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Piper Jaffray Starts Neothetics Inc. (NEOT) at Overweight
December 15, 2014 6:39 AM ESTPiper Jaffray initiates coverage on Neothetics Inc. (NASDAQ: NEOT) with a Overweight rating and a price target of $20.00.
Analyst David Amsellem comments, "NEOT, in our view, is well positioned to expand and transform the emerging body contouring space with LIPO-202, an injectable form... More
Guggenheim Starts Neothetics Inc. (NEOT) at Buy
December 15, 2014 6:04 AM ESTGuggenheim initiates coverage on Neothetics Inc. (NASDAQ: NEOT) with a Buy rating and a price target of $16.00.
Analyst Louise Chen highlighted the company's two products in development:
LIPO-202 (Salmeterol Xinafoate for Injection): Injectable designed to produce local, selective fat tissue reduction (pharmaceutical lipoplasty).LIPO-102 (Salmeterol Xinafoate and Fluticasone Propionate): Orphan designation for treatment of... More